Metabolon Competitors and Similar CompaniesClear all
Metabolon's competitors and similar companies include PolyPid, Adaptimmune, VBI Vaccines and Travecta Therapeutics.
 Metabolon Global leader in metabolomics for precision medicine, biomarker discovery, and advancing pharma & life sciences research. |  PolyPid PolyPid is a company developing a technology platform that enables a controlled and prolonged release of active pharmaceutical ingredients (API). |  Adaptimmune Adaptimmune Limited develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. |  VBI Vaccines VBI Vaccines is a biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. | ||
Founding Date | Founding Date 2000 | Founding Date 2008 | Founding Date 2008 | Founding Date 2001 | Founding Date 2017 |
Type | Type Private | Type Public | Type Public | Type Public | Type Private |
Tags | |||||
Locations | Locations Morrisville, US HQ Hallbergmoos, DE München, DE | Locations Petah Tikva, IL HQ Summit, US | Locations Philadelphia, US HQ Milton, GB Milton, GB Stevenage, GB | Locations Cambridge, US HQ Ottawa, CA Rehovot, IL | Locations New York, US HQ Singapore, SG |
Employees | Employees 1911% increase | Employees 57 | Employees 4007% decrease | Employees 12314% increase | Employees 625% decrease |
Valuation ($) | Valuation ($) N/A | Valuation ($) 23.7 m | Valuation ($) 188.5 m | Valuation ($) 1.9 m | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $178m (FY, 2024) | Revenue (est.) $8.7m (FY, 2023) | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods $70k (FY, 2024) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit $178m (FY, 2024) | Gross profit N/A | Gross profit N/A |
Net income | Net income N/A | Net income ($34.2m) (FY, 2025) | Net income ($70.8m) (FY, 2024) | Net income ($92.8m) (FY, 2023) | Net income N/A |
Operating ⚠ | |||||
Patent Applications | Patent Applications N/A | Patent Applications 49 (FY, 2017) | Patent Applications 69 (FY, 2016) | Patent Applications N/A | Patent Applications N/A |
Patents Issued | Patents Issued N/A | Patents Issued 104 (FY, 2017) | Patents Issued 173 (FY, 2016) | Patents Issued N/A | Patents Issued N/A |
Funding | |||||
Latest funding round | Latest funding round $ 15m (over 9 years ago) | Latest funding round N/A | Latest funding round N/A | Latest funding round N/A | Latest funding round $ 15m (almost 6 years ago) |
Total funding raised | Total funding raised $ 95.4m | Total funding raised $ 103.8m | Total funding raised $ 107.5m | Total funding raised N/A | Total funding raised $ 15m |
For sources of this data, please see the company profile
View Company Profiles
PolyPid
HQ
Petah Tikva, IL
Employees
57
PolyPid is a company developing a technology platform that enables a controlled and prolonged release of active pharmaceutical ingredients (API).
View companyAdaptimmune
HQ
Philadelphia, US
Employees
400↓ 7% decrease
Adaptimmune Limited develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases.
View companyVBI Vaccines
HQ
Cambridge, US
Employees
123↑ 14% increase
VBI Vaccines is a biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology.
View company
Travecta Therapeutics
HQ
New York, US
Employees
6↓ 25% decrease
Travecta Therapeutics is a biotechnology company.
View company